AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Seletalisib (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacokinetics
- 05 Mar 2018 Status changed from recruiting to completed.
- 13 Feb 2018 The study has been completed in France according to European Clinical Trials Database record.
- 09 Feb 2018 The study has been completed in Germany.